Compare PRSU & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRSU | NEO |
|---|---|---|
| Founded | 1926 | 2001 |
| Country | United States | United States |
| Employees | 2100 | N/A |
| Industry | Business Services | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | N/A | 2008 |
| Metric | PRSU | NEO |
|---|---|---|
| Price | $45.45 | $11.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $31.67 | $13.38 |
| AVG Volume (30 Days) | 194.5K | ★ 1.2M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.85 | $10.63 |
| Revenue Next Year | $4.94 | $9.73 |
| P/E Ratio | $3.45 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.92 | $4.72 |
| 52 Week High | $45.75 | $13.74 |
| Indicator | PRSU | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 63.45 | 72.21 |
| Support Level | $32.34 | $7.50 |
| Resistance Level | $45.61 | $12.60 |
| Average True Range (ATR) | 1.18 | 0.56 |
| MACD | -0.07 | 0.18 |
| Stochastic Oscillator | 91.92 | 96.14 |
Pursuit Attractions and Hospitality Inc is an attractions and hospitality company that owns and operates a collection of inspiring and unforgettable experiences at iconic destinations across the United States, Canada, Iceland and Costa Rica. Its elevated hospitality offerings include point-of-interest attractions and distinctive lodges, as well as integrated restaurants, retail options, and transportation that allow visitors to discover and connect with breathtaking national parks and renowned travel locations.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.